Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran, chemically (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a selective agonist for human hydroxycarboxylic acid receptors HM74A (GPR109A) and GPR109B, facilitating precise modulation of lipid metabolism in research settings (Ye et al., 2025). Recent cryo-EM studies have resolved Acifran-receptor complexes at high resolution, confirming the atomic basis for selectivity and binding (DOI:10.1371/journal.pbio.3003480). Acifran demonstrates low solubility in ethanol and DMSO (<21.82 mg/ml) and requires storage at -20°C for optimal integrity (APExBIO). It is not suitable for diagnostic or medical use but is essential for GPCR ligand binding and lipid signaling studies. Acifran's structural validation enables reproducibility and assay sensitivity, distinguishing it among hypolipidemic research agents.

Biological Rationale

Lipid metabolism is regulated by G-protein coupled receptors (GPCRs), including HM74A/GPR109A and GPR109B. These receptors, also classified as hydroxycarboxylic acid receptors (HCAR2 and HCAR3), are critical for sensing metabolic intermediates and mediating anti-lipolytic signaling (Ye et al., 2025). Dysregulation of these pathways contributes to metabolic disorders such as dyslipidemia, hyperlipidemia, atherosclerosis, and cardiovascular disease. Agonists like Acifran enable researchers to probe receptor-ligand interactions and dissect downstream signaling relevant to lipid regulation. The selectivity of Acifran for these receptors supports focused mechanistic studies without off-target effects typical of less specific compounds (see also), extending earlier work on generic hypolipidemic agents.

Mechanism of Action of Acifran

Acifran acts as a selective agonist at HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) receptors. Upon binding, it induces conformational changes in the receptor, promoting coupling with Gi-type G-proteins. This results in inhibition of adenylyl cyclase and decreased intracellular cAMP, leading to suppression of lipolysis in adipocytes (Ye et al., 2025). Cryo-EM structures demonstrate Acifran occupying the orthosteric binding site, engaging in π–π interactions with key amino acid residues (notably F1073.32 in HCAR3), which underpins its selectivity (Ye et al., Fig. 3). The effect is context-dependent and is not associated with cutaneous flushing, differentiating it from other HCAR2 agonists.

Evidence & Benchmarks

• Acifran binds HM74A/GPR109A and GPR109B with high selectivity, as confirmed by cryo-EM structures at 2.72–3.18 Å resolution (Ye et al., 2025).
• Ligand-receptor complex coordinates for Acifran-bound HCAR3 (PDB: 9JKX) and HCAR2 (PDB: 9JKY) are available in the Protein Data Bank (PDB 9JKX).
• Functional cAMP assays in HEK-293 cells show Acifran-induced signaling via Gi-coupled pathways (Ye et al., Table 1).
• Acifran has a molecular weight of 218.21 g/mol and a chemical formula of C12H10O4 (APExBIO product sheet).
• Storage at -20°C preserves compound integrity; solutions are recommended for short-term use only (APExBIO).

This article extends the mechanistic depth provided in Redefining Lipid Metabolism Research by integrating new atomic-resolution evidence for Acifran’s selectivity, and updates Acifran and the Next Frontier with direct cryo-EM data, offering experimentally grounded guidance.

Applications, Limits & Misconceptions

Acifran is used extensively for:

• Studying GPCR ligand binding and selectivity in lipid metabolism regulation.
• Elucidating molecular mechanisms of anti-lipolytic signaling pathways.
• Developing and benchmarking high-throughput assays for metabolic disorder research (see review).
• Enabling reproducible, structure-guided design of new hypolipidemic agents targeting HM74A/GPR109A and GPR109B.

However, Acifran is not intended for clinical, diagnostic, or therapeutic use. Its utility is restricted to in vitro and ex vivo experimental systems. The selectivity profile, while high, may not predict in vivo pharmacokinetics or safety. Off-target effects outside the HCAR2/3 family have not been fully characterized.

Common Pitfalls or Misconceptions

• Acifran is not a drug candidate; it is for research use only (APExBIO).
• Solubility in aqueous buffers is limited; exceeding 21.82 mg/ml in DMSO or ethanol can lead to precipitation.
• Long-term solutions degrade rapidly; always prepare fresh aliquots for experiments.
• Acifran does not activate unrelated GPCRs or nuclear receptors under standard assay conditions (Ye et al., SI).
• It does not induce HCAR2-mediated cutaneous flushing, a side effect observed with some other agonists.

Workflow Integration & Parameters

Acifran (SKU B6848, APExBIO) is supplied as an off-white solid. For lipid signaling pathway studies:

• Dissolve in DMSO or ethanol up to 21.82 mg/ml; vortex or sonicate as needed.
• Aliquot and store at -20°C; avoid repeated freeze-thaw cycles.
• Prepare working solutions immediately before use to maintain activity.
• In cell-based assays, confirm receptor expression and use appropriate negative controls.
• Structural studies may use the published coordinates (PDB 9JKX, 9JKY) for molecular docking or simulation.

Researchers seeking scenario-based guidance can consult Acifran: Hypolipidemic Agent for Lipid Metabolism Research, which benchmarks Acifran’s reproducibility and assay sensitivity. This article clarifies the molecular basis for these properties with direct structural data.

Conclusion & Outlook

Acifran is a rigorously validated HM74A/GPR109A and GPR109B agonist essential for modern lipid metabolism research. Its structural elucidation at atomic resolution enables precise, reproducible interrogation of GPCR-mediated signaling pathways (Ye et al., 2025). The compound’s stability, selectivity, and performance parameters are well characterized, offering a robust platform for both mechanistic and translational research. As research into metabolic disorders advances, Acifran—available from APExBIO—will remain a cornerstone reagent for studies of lipid regulation and signaling.